BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr 2008;32:613-21. [PMID: 18974239 DOI: 10.1177/0148607108321702] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Weinberg JB, Yeo TW, Mukemba JP, Florence SM, Volkheimer AD, Wang H, Chen Y, Rubach M, Granger DL, Mwaikambo ED, Anstey NM. Dimethylarginines: endogenous inhibitors of nitric oxide synthesis in children with falciparum malaria. J Infect Dis 2014;210:913-22. [PMID: 24620026 DOI: 10.1093/infdis/jiu156] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
2 Saracyn M, Patera J, Kocik J, Brytan M, Zdanowski R, Lubas A, Kozłowski W, Wańkowicz Z. Strain of experimental animals and modulation of nitric oxide pathway: their influence on development of renal failure in an experimental model of hepatorenal syndrome. Arch Med Sci. 2012;8:555-562. [PMID: 22852015 DOI: 10.5114/aoms.2012.29281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
3 Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res 2009;60:448-60. [PMID: 19682580 DOI: 10.1016/j.phrs.2009.08.002] [Cited by in Crossref: 164] [Cited by in F6Publishing: 151] [Article Influence: 12.6] [Reference Citation Analysis]
4 Yeo TW, Lampah DA, Tjitra E, Gitawati R, Darcy CJ, Jones C, Kenangalem E, McNeil YR, Granger DL, Lopansri BK, Weinberg JB, Price RN, Duffull SB, Celermajer DS, Anstey NM. Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog 2010;6:e1000868. [PMID: 20421938 DOI: 10.1371/journal.ppat.1000868] [Cited by in Crossref: 54] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
5 Di Pasqua LG, Berardo C, Rizzo V, Richelmi P, Croce AC, Vairetti M, Ferrigno A. MCD diet-induced steatohepatitis is associated with alterations in asymmetric dimethylarginine (ADMA) and its transporters. Mol Cell Biochem 2016;419:147-55. [PMID: 27357826 DOI: 10.1007/s11010-016-2758-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
6 Mindikoglu AL, Dowling TC, Magder LS, Christenson RH, Weir MR, Seliger SL, Hutson WR, Howell CD. Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines. Clin Gastroenterol Hepatol 2016;14:624-632.e2. [PMID: 26133903 DOI: 10.1016/j.cgh.2015.06.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
7 Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci 2020;21:E9646. [PMID: 33348908 DOI: 10.3390/ijms21249646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
8 Davids M, van Hell AJ, Visser M, Nijveldt RJ, van Leeuwen PA, Teerlink T. Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine. Am J Physiol Heart Circ Physiol. 2012;302:H1762-H1770. [PMID: 22367507 DOI: 10.1152/ajpheart.01205.2011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
9 Davids M, Richir MC, Visser M, Ellger B, van den Berghe G, van Leeuwen PA, Teerlink T. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness. Metabolism. 2012;61:482-490. [PMID: 22000584 DOI: 10.1016/j.metabol.2011.08.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
10 Czarnecka A, Milewski K, Jaźwiec R, Zielińska M. Intracerebral Administration of S-Adenosylhomocysteine or S-Adenosylmethionine Attenuates the Increases in the Cortical Extracellular Levels of Dimethylarginines Without Affecting cGMP Level in Rats with Acute Liver Failure. Neurotox Res 2017;31:99-108. [PMID: 27604291 DOI: 10.1007/s12640-016-9668-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
11 Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol 2013;38:345-54. [PMID: 24107793 DOI: 10.1159/000355540] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
12 Blackwell S, O’reilly DSJ, Reid D, Talwar D. Plasma dimethylarginines during the acute inflammatory response: ADMA DURING ACUTE INFLAMMATORY RESPONSE. European Journal of Clinical Investigation 2011;41:635-41. [DOI: 10.1111/j.1365-2362.2010.02451.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
13 He H, Li X, Wang H, Zhang W, Jiang H, Wang S, Yuan L, Liu Y, Liu X. Effects of Salvianolic Acid A on Plasma and Tissue Dimethylarginine Levels in a Rat Model of Myocardial Infarction: . Journal of Cardiovascular Pharmacology 2013;61:482-8. [DOI: 10.1097/fjc.0b013e3182893fd5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pilz S, Putz-Bankuti C, Meinitzer A, März W, Kienreich K, Stojakovic T, Pieber TR, Stauber RE. Association of homoarginine and methylarginines with liver dysfunction and mortality in chronic liver disease. Amino Acids 2015;47:1817-26. [PMID: 25952253 DOI: 10.1007/s00726-015-2000-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
15 Kasumov T, Edmison JM, Dasarathy S, Bennett C, Lopez R, Kalhan SC. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism 2011;60:776-81. [PMID: 20869086 DOI: 10.1016/j.metabol.2010.07.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
16 Bajaj JS, Ahluwalia V, Wade JB, Sanyal AJ, White MB, Noble NA, Monteith P, Fuchs M, Sterling RK, Luketic V, Bouneva I, Stravitz RT, Puri P, Kraft KA, Gilles H, Heuman DM. Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis. J Hepatol 2013;58:38-44. [PMID: 22889958 DOI: 10.1016/j.jhep.2012.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
17 Ferrigno A, Rizzo V, Bianchi A, Di Pasqua LG, Berardo C, Richelmi P, Vairetti M. Changes in ADMA/DDAH pathway after hepatic ischemia/reperfusion injury in rats: the role of bile. Biomed Res Int. 2014;2014:627434. [PMID: 25243167 DOI: 10.1155/2014/627434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
18 Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 2011;10:277-91. [DOI: 10.1038/nrd3358] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 9.6] [Reference Citation Analysis]
19 Holecek M. Ammonia and amino acid profiles in liver cirrhosis: Effects of variables leading to hepatic encephalopathy. Nutrition 2015;31:14-20. [DOI: 10.1016/j.nut.2014.03.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
20 Zhao Y, Zhao G, Chen Z, She Z, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension 2020;75:275-84. [DOI: 10.1161/hypertensionaha.119.13419] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 10.5] [Reference Citation Analysis]
21 Boga S, Alkim H, Koksal AR, Bayram M, Ozguven MBY, Ergun M, Neijmann ST, Ozgon G, Alkim C. Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology. Journal of Investigative Medicine 2015;63:871-7. [DOI: 10.1097/jim.0000000000000230] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
22 Mindikoglu AL, Pappas SC. New Developments in Hepatorenal Syndrome. Clin Gastroenterol Hepatol 2018;16:162-177.e1. [PMID: 28602971 DOI: 10.1016/j.cgh.2017.05.041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
23 Huang S, Xu Y, Peng WF, Cheng J, Li HH, Shen LS, Xia LL. Asymmetric dimethylarginine targets MAPK pathway to regulate insulin resistance in liver by activating inflammation factors. J Cell Biochem 2018. [PMID: 30506883 DOI: 10.1002/jcb.28021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 2010;47:17-28. [PMID: 19940201 DOI: 10.1258/acb.2009.009196] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]